• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4602056)   Today's Articles (6064)   Subscriber (49366)
For: Dong J, Wang TL, Lu J, Ding CZ, Hu L, Hu G, He H, Zeng X, Li X, Sun D, Zhu Y, Shen L, Gu Q, Chan CC, Xia Y, Li J, Chen S. Design, syntheses and evaluations of novel indole derivatives as orally selective estrogen receptor degraders (SERD). Bioorg Med Chem Lett 2020;30:127601. [PMID: 33035677 DOI: 10.1016/j.bmcl.2020.127601] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Revised: 09/29/2020] [Accepted: 10/01/2020] [Indexed: 11/16/2022]
Number Cited by Other Article(s)
1
Wang R, Huang R, Yuan Y, Wang Z, Shen K. The anti-breast cancer potential of indole/isatin hybrids. Arch Pharm (Weinheim) 2023;356:e2300402. [PMID: 37650315 DOI: 10.1002/ardp.202300402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2023] [Revised: 08/15/2023] [Accepted: 08/16/2023] [Indexed: 09/01/2023]
2
Yao J, Tao Y, Hu Z, Li J, Xue Z, Zhang Y, Lei Y. Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future. Front Pharmacol 2023;14:1225951. [PMID: 37808197 PMCID: PMC10551544 DOI: 10.3389/fphar.2023.1225951] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2023] [Accepted: 09/05/2023] [Indexed: 10/10/2023]  Open
3
Manna S, Paul S, Kong WY, Aich D, Sahoo R, Tantillo DJ, Panda S. Stereodivergent Zweifel Olefination and its Mechanistic Dichotomy. Angew Chem Int Ed Engl 2023;62:e202309136. [PMID: 37495925 DOI: 10.1002/anie.202309136] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Revised: 07/24/2023] [Accepted: 07/26/2023] [Indexed: 07/28/2023]
4
Bhatia N, Hazra S, Thareja S. Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview. Eur J Med Chem 2023;256:115422. [PMID: 37163948 DOI: 10.1016/j.ejmech.2023.115422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 04/17/2023] [Accepted: 04/26/2023] [Indexed: 05/12/2023]
5
Scott JS, Barlaam B. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present). Expert Opin Ther Pat 2021;32:131-151. [PMID: 34763600 DOI: 10.1080/13543776.2022.2006185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA